PAK4/NAMPT inhibitor KPT-9274 synergizes with Sunitinib in Pancreatic Neuroendocrine Tumor Cellular Models
PAK4/NAMPT inhibitor KPT-9274 synergizes with Sunitinib in Pancreatic Neuroendocrine Tumor Cellular Models
Click Poster To View Full PDF
Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
About
NETRFThe Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
-
For Researchers
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.